AviadoBio Advances Novel Gene Therapy for a Form of Early-Onset Dementia

LONDON – March 31, 2026 – In a significant step forward for neurodegenerative disease research, London-based AviadoBio has initiated the fourth dose-escalation cohort in its ASPIRE-FTD clinical trial. The Phase 1/2 study is evaluating AVB-101, an investigational one-time gene therapy for individuals with frontotemporal dementia caused by mutations in the progranulin gene (FTD-GRN), a devastating condition with no approved disease-modifying treatments.

This advancement builds on encouraging early results from the trial, which has already dosed 12 patients across three continents. The company reports a favorable safety profile and positive biomarker data, signaling that the therapy may be effectively addressing the underlying genetic cause of the disease. The news, coupled with recent strategic funding from leading dementia research foundations, reinforces the growing momentum behind precision gene therapies for complex brain disorders.

A Precision Strike Against a Devastating Disease

Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder that typically strikes in mid-life, between the ages of 45 and 65. Unlike Alzheimer's, which primarily affects memory, FTD targets the frontal and temporal lobes of the brain, leading to profound changes in personality, behavior, and language. For families, the impact is immense, as loved ones lose their ability to communicate, manage daily life, and maintain their social and emotional connections.

The specific subtype targeted by AviadoBio, FTD-GRN, accounts for 5-10% of all FTD cases and is caused by a mutation in one copy of the GRN gene. This genetic flaw results in insufficient production of a critical protein called progranulin, which is vital for neuronal survival and proper lysosomal function. Without enough progranulin, brain cells become damaged and die, leading to the relentless progression of the disease.

AVB-101 is designed to directly counteract this deficiency. It uses a well-studied and safe viral vector (AAV) to deliver a functional copy of the GRN gene directly to brain cells. The therapeutic challenge, however, has always been delivery. The brain is protected by the formidable blood-brain barrier, which prevents most drugs and therapies from reaching their intended targets.

AviadoBio is tackling this with a novel and highly precise approach. AVB-101 is administered via a minimally invasive, MRI-guided stereotactic neurosurgical procedure that delivers the therapy directly into the thalamus. This deep-brain structure acts as a central relay station with extensive neural connections to other parts of the brain, including the frontal and temporal lobes that are ravaged by FTD. By targeting the thalamus, the company aims to achieve widespread distribution of the therapy to the cortical regions where it is needed most, while using a lower overall dose and minimizing potential side effects elsewhere in the body.

Encouraging Signs from Early Trial Data

The decision to advance to a fourth, higher-dose cohort was supported by promising findings from the first 12 patients enrolled in the ASPIRE-FTD trial. According to AviadoBio, early data demonstrates dose-dependent elevations in progranulin levels within the cerebrospinal fluid (CSF). This is a critical biomarker finding. It provides strong evidence of target engagement, suggesting that the delivered gene is successfully instructing brain cells to produce the missing protein, thereby correcting the core biological deficit of FTD-GRN.

Equally important is the therapy's safety profile. The company reported that AVB-101 has been well-tolerated to date, with no serious adverse events related to the treatment. Crucially, patients have not required prophylactic or reactive immunosuppression. The need for long-term immunosuppressive drugs, which can carry their own significant health risks, has been a major hurdle for some gene therapies. The ability to avoid this complication represents a significant advantage for AVB-101, simplifying the treatment regimen and improving the potential risk-benefit profile for patients. AviadoBio plans to share more detailed data with the scientific community at the Alzheimer's Association International Conference (AAIC) in July 2026 and the International Society for Frontotemporal Dementias (ISFTD) meeting in October 2026.

Strategic Backing in a Competitive Field

The promise of AVB-101 has attracted key support from organizations at the forefront of the fight against dementia. AviadoBio recently received an investment from the Treat FTD Fund, a venture philanthropy initiative launched by The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD). This funding not only provides financial resources but also serves as a powerful validation of the scientific approach from two of the most respected organizations in the field.

“We are focused on continuing to advance AVB-101 building on the encouraging data we’ve seen so far,” said Lisa Deschamps, Chief Executive Officer of AviadoBio, in a statement. “We are thrilled to now have the ADDF and the AFTD’s support on this important mission as we progress the ASPIRE-FTD trial.”

The company is navigating a high-risk, high-reward landscape. Last year, Eli Lilly discontinued development of its own FTD-GRN gene therapy program, underscoring the immense challenges in this therapeutic area. However, other companies, such as Passage Bio, are also advancing similar gene replacement therapies, creating a competitive race to be the first to deliver a breakthrough for patients. AviadoBio has solidified its position by securing full worldwide development and commercialization rights to AVB-101, following the expiration of a previous option and license agreement with Astellas, which remains a shareholder. This move grants the company complete strategic control over the program's future.

With 20 active trial sites across North America and Europe, the ASPIRE-FTD study continues to recruit patients, moving the field closer to a potential future where a one-time treatment could alter the course of this devastating form of dementia. While the path to approval is long and rigorous, each step forward in trials like this provides a crucial glimmer of hope for patients and families awaiting a cure.